Valo Therapeutics, a Helsinki, Finland-based developer of adaptable immunotherapies for cancer and infectious diseases, raised €2.23M from the European Innovation Council.
The company intends to use the funds for a project to progress its innovative PeptiCHIP technology.
for a project to progress the company’s innovative PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies.
The project, which will be fully funded by the EIC with a 100%, non-dilutive, grant is called “Pre-clinical validation and demonstration of PeptiCHIP”. ValoTx also gains access to EIC Business Acceleration Services including coaching, mentoring, and partnering events.
Led by CEO Paul Higham, Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious disease. Its lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into powerful activators of systemic anti-tumor cytotoxic T-cell immunity without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiCHIP, PeptiENV and PeptiVAX, among other neoantigen strategies. Novel microchip based PeptiCHIP technology rapidly identifies a tumor’s ‘fingerprints’ to drive development of novel personalized immunotherapies. PeptiENV is expected to improve the therapeutic response to oncolytic enveloped viruses in the treatment of multiple forms of cancer, while PeptiVAX is a program to develop a novel, adaptable anti-infectives vaccination platform.
FinSMEs
14/02/2023